SEC and Kiromic settle over biotech’s failure to disclose clinical trial holds ahead of stock offering

The SEC said Tues­day that it set­tled charges filed against Kiromic Bio­Phar­ma, a tiny im­muno-on­col­o­gy start­up based in Texas, for fail­ing to dis­close clin­i­cal holds …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.